Quantum Biopharma’s Novel MS Drug Passes Phase 1 Safety Test

Quantum Biopharma said a full Clinical Study Report from its Phase 1 multiple-ascending-dose trial found that Lucid-21-302, a first-in-class, non-immunomodulatory compound aimed at preventing demyelination in multiple sclerosis, was safe and well-tolerated in healthy volunteers. The clean safety profile enables the Toronto-based company to include the data in an upcoming Investigational New Drug filing with the U.S. Food and Drug Administration and move the therapy into patient-focused efficacy studies. Separately, Clearmind Medicine received Institutional Review Board clearance from Hadassah Medical Center in Jerusalem to enroll participants in a Phase 1/2a study of CMND-100 for Alcohol Use Disorder. The approval follows prior U.S. FDA IND clearance and IRB sign-offs at Yale, Johns Hopkins and other sites, allowing the multinational trial to proceed with first-in-human testing of the psychedelic-derived oral therapy.